HK Innoen Launches 'K-Cab Orally Disintegrating Tablets'

HK Innoen's Gastroesophageal Reflux Disease Treatment 'K-CAB Orally Disintegrating Tablet'

[Asia Economy Reporter Chunhee Lee] On the 2nd, HK inno.N announced that it had launched the gastroesophageal reflux disease treatment drug ‘K-CAB Orally Disintegrating Tablet’ the day before.

K-CAB Orally Disintegrating Tablet is a formulation that dissolves in the mouth. It helps patients who have difficulty swallowing pills or are in situations where drinking water is difficult to take the medication conveniently. A peppermint flavor was added to minimize discomfort related to taste. HK inno.N plans to further solidify K-CAB’s market position by expanding the prescription range through the launch of the orally disintegrating tablet following the K-CAB tablet.

K-CAB, a new P-CAB class drug for gastroesophageal reflux disease, recorded a cumulative outpatient prescription performance of 246.6 billion KRW until March after the tablet was launched in 2019. In Korea, both the tablet and orally disintegrating tablet have been approved for a total of four indications: erosive and non-erosive gastroesophageal reflux disease, gastric ulcer, and combination antibiotic therapy for Helicobacter pylori eradication. Among these, insurance coverage is applied to three indications including gastric ulcer.

An HK inno.N official said, "By introducing the orally disintegrating tablet three years after the launch of the K-CAB tablet, we expect more active customized prescriptions considering patient characteristics in the future," adding, "We will continue differentiated clinical trials and research to expand indications to maximize K-CAB’s competitiveness."

This content was produced with the assistance of AI translation services.